Lack of effect of oral selenite on p53 associated gene expression during TL01 therapy of psoriasis patients

Photodermatol Photoimmunol Photomed. 2007 Apr-Jun;23(2-3):98-100. doi: 10.1111/j.1600-0781.2007.00277.x.


Selenium (Se) has protective properties against ultraviolet (UV)-induced changes in skin cells in vitro but little is known about such activity in human subjects. In the present study, seven patients with psoriasis ingested 400 microg of sodium selenite daily during a 4 week course of whole-body narrow-band UVB (TL01) therapy while six more psoriasis patients, similarly irradiated, ingested a placebo. Skin biopsies, collected at the start and end of the phototherapy were analysed for phosphorylated p53, Fas, Bcl-2, Bax and oxidized guaninosine, and for numbers of Langerhans and sunburn cells. Following the TL01 therapy, no significant difference was observed for any of these markers when the Se group was compared with the placebo group of patients, although p53 and Bcl-2 expression decreased in the Se supplemented group.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Combined Modality Therapy
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Psoriasis / pathology
  • Psoriasis / radiotherapy*
  • Severity of Illness Index
  • Sodium Selenite / administration & dosage
  • Sodium Selenite / therapeutic use*
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism*
  • Ultraviolet Rays*
  • Ultraviolet Therapy


  • Tumor Suppressor Protein p53
  • Sodium Selenite